Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
复制标题
骨转移对接受免疫检查点抑制剂治疗的晚期非小细胞肺癌患者临床结局的不利影响
DOI：
10.1111/1759-7714.13597
复制
发表时间：
2020-10
期刊：
影响因子：
2.9
通讯作者：
Su C
中科院分区：
文献类型：
--
作者：
Li X;Wang L;Chen S;Zhou F;Zhao J;Zhao W;Su C
骨转移（BoM）在晚期非小细胞肺癌（NSCLC）患者中很常见，被认为是预后不良因素之一。然而，BoM对接受免疫检查点抑制剂（ICI）治疗的晚期NSCLC患者临床结局的影响仍不清楚。回顾性分析了103例接受ICI单药治疗的患者和101例接受ICI联合化疗或抗血管生成治疗的患者。研究了BoM+和BoM-之间的无进展生存期（PFS）、总生存期（OS）和客观缓解率（ORR）的差异。在接受联合治疗的101例患者中，BoM−和BoM+之间的中位PFS和中位OS均无显著差异（中位PFS，10.1 vs. 12.1个月，P = 0.6;中位OS，NR vs. 24.6个月，P = 0.713）。相比之下，在接受ICI单药治疗的103例患者中，BoM+患者的PFS（4.2 vs. 6.7个月，P = 0.0484）和OS（12.5 vs. 23.9个月，P = 0.0036）低于BoM−患者。ICI单药治疗组的单变量和多变量分析也将BoM确定为削弱ICI单药治疗疗效的独立因素。在所有接受ICI单药治疗的BoM+患者中，姑息性放疗和双膦酸盐药物均未改善OS（姑息性放疗：12.5 vs. 16.7个月，P = 0.487;双膦酸盐药物：12.5 vs. 9.7个月，P = 0.568）。BoM减弱了ICI单药治疗晚期NSCLC患者的疗效。在接受ICI单药治疗的BoM+患者中，姑息性放疗和双膦酸盐药物均不能改善OS。BoM患者需要其他治疗策略。骨转移在晚期非小细胞肺患者中很常见，被认为是不良预后因素之一，但骨转移对免疫检查点抑制剂临床结局的影响仍不清楚。我们的研究表明，骨转移减弱了晚期NSCLC患者中ICI单药治疗的疗效。在接受ICI单药治疗的骨转移患者中，姑息性放疗或双膦酸盐药物均未改善OS。
Bone metastasis (BoM) is common in patients with advanced non‐small cell lung cancer (NSCLC) and considered as one of the negative prognostic factors. However, the impact of BoM on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors (ICIs) remains unclear. A total of 103 patients treated with ICI monotherapy and 101 patients treated with ICIs combined with chemotherapy or antiangiogenesis therapy were retrospectively analyzed. The differences in progression‐free survival (PFS), overall survival (OS) and objective response rate (ORR) between BoM+ and BoM− were investigated. Of those 101 patients who received combination therapy, no significant difference between BoM− and BoM+ in terms of both median PFS and median OS (median PFS, 10.1 vs. 12.1 months, P = 0.6; median OS, NR vs. 24.6 months, P = 0.713) was determined. In contrast, of the 103 patients who received ICI monotherapy, BoM+ patients had an inferior PFS (4.2 vs. 6.7 months, P = 0.0484) and OS (12.5 vs. 23.9 months, P = 0.0036) compared with BoM− patients. The univariate and multivariate analysis in the ICI monotherapy group also identified BoM as an independent factor attenuating the efficacy of ICI monotherapy. Of all BoM+ patients who received ICI monotherapy, neither palliative radiotherapy nor bisphosphonate drugs improved OS (palliative radiotherapy: 12.5 vs. 16.7 months, P = 0.487; bisphosphonate drugs: 12.5 vs. 9.7 months, P = 0.568). BoM attenuated the efficacy of ICI monotherapy in patients with advanced NSCLC. Of BoM+ patients who received ICI monotherapy, neither palliative radiotherapy nor bisphosphonate drugs improved OS. Other therapeutic strategies are needed for patients with BoM. Bone metastasis is common in patients with advanced non‐small cell lung and considered as one of the negative prognostic factors, but the impact of bone metastases on clinical outcomes of immune checkpoint inhibitors remains unclear. Our study demonstrated that bone metastases attenuated the efficacy of ICIs monotherapy in patients with advanced NSCLC. Of patients with bone metastases who received ICIs monotherapy, neither palliative radiotherapy nor bisphosphonate drugs improved OS.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
紫杉醇的抗肿瘤作用是通过抑制髓样衍生的抑制细胞和自发黑色素瘤模型中的慢性炎症来介导的。
DOI：
10.4049/jimmunol.1202781
发表时间：
2013-03-01
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Sevko A;Michels T;Vrohlings M;Umansky L;Beckhove P;Kato M;Shurin GV;Shurin MR;Umansky V
通讯作者：
Umansky V
联合放疗与抗PD-L1抗体协同增强非小细胞肺癌的抗肿瘤作用
影响因子：
20.4
作者：
Gong, Xiaomei;Li, Xuefei;Zhou, Caicun
通讯作者：
Zhou, Caicun
影响因子：
3.4
作者：
Kuchuk M;Addison CL;Clemons M;Kuchuk I;Wheatley-Price P
通讯作者：
Wheatley-Price P
影响因子：
20.4
作者：
Scagliotti, Giorgio Vittorio;Hirsh, Vera;Jacobs, Ira
通讯作者：
Jacobs, Ira